The contract comprises a $1.74bn award to produce and supply these vaccine doses and options to further procure up to 234 million additional doses of the company’s booster candidates.
A bivalent booster candidate, the mRNA-1273.222 vaccine comprises Spikevax along with the Omicron BA.4/5 strain messenger RNA (mRNA).
Spikevax is the company’s Covid-19 vaccine intended for active immunisation for disease prevention in people aged 18 years and above.
The initial vaccine doses of 66 million are anticipated to be supplied this year. On the US exercising options, the doses could total 300 million.
Last month, the company announced the advancement of two bivalent candidates based on various population health security approaches in different countries.
The mRNA-1273.222 vaccine containing the BA.4/5 Omicron strain is being developed in line with the latest recommendations from the Food and Drug Administration (FDA).
Another vaccine, mRNA-1273.214, comprises the BA.1 Omicron strain, which could be of benefit as observed by the World Health Organization (WHO).
On obtaining authorisations, these updated bivalent vaccines could potentially provide enhanced, wider and long-lasting protection against Covid-19.
Moderna CEO Stéphane Bancel said: “Moderna’s mRNA platform is enabling us to rapidly create mRNA-1273.222, a bivalent vaccine that specifically targets Omicron subvariants BA.4 and BA.5, the most prevalent variants of concern in the US today.
“We remain fully committed to leveraging our innovative technology platform to offer tailored vaccines that help protect communities against Covid-19.”
The US Department of Health and Human Services, and Administration for Strategic Preparedness and Response (ASPR) and others are supporting the deal through federal funds.
In June, the company and the European Commission (EC) signed an agreement to amend their previously agreed contractual supply schedules for the former’s Covid-19 vaccine booster product (Spikevax, mRNA-1273) or updated booster vaccine candidate.
Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.
Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.